No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRSN240816P2500
- 0.45
- 0.000.00%
15min DelayNot Open Jul 19 15:59 ET
0.00High0.00Low
0.00Open0.45Pre Close0 Volume188 Open Interest2.50Strike Price0.00Turnover0.00%IV-4.06%PremiumAug 16, 2024Expiry Date0.53Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.38Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 25%
To the annoyance of some shareholders, Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis
Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)
Comments
Despite a recent share price hike, Mersana Therapeutics' P/S ratio lags behind others due to forecasted revenue decline. Without major changes, a drastic stock price rise is unlikely.
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 31% But Its Business Still Trails The IndustryMersana Therapeutics forecasted future revenue decline contributes to lower P/S ratio, limiting strong rise potential in share prices. The market expects performance drop, keeping P/S suppressed. For P/S to avoid further fall, top-line growth needs improvement.
$Mersana Therapeutics(MRSN.US$ some that r buying on cashappyall better load up while u can before they take away the buy button
1
4
$Mersana Therapeutics(MRSN.US$
glad i sold a little on time. lol
glad i sold a little on time. lol
2
3
Read more